News from other sources ...

Medical devices and equipment

Medical device security is flawed, but the fix isn't going to happen overnight. And there's no one entity to blame, according to Dale Nordenberg, executive director of MDISS (Medical Device Innovation, Safety and Security Consortium).

Pharmaceuticals

A new patient advocacy group launches Wednesday that distinguishes itself by focusing only on drug prices and eschewing money from the pharmaceutical industry at a time when drug makers are pouring millions into a campaign fighting efforts to regulate them.

The latest deal for a priority review voucher suggests prices are finally falling | STAT

In a noteworthy deal, Gilead Sciences agreed to pay $125 million to Sarepta Therapeutics for a priority review voucher. But one Wall Street analyst expressed disappointment over the price tag and suggested the deal raises questions about how much these controversial vouchers can fetch going forward.

Carl Icahn takes stake in Bristol-Myers Squibb | The Wall Street Journal

The same day Bristol-Myers Squibb Co. shook up its board to satisfy one activist investor, the drugmaker was faced with another: Carl Icahn, whose interest is fueling speculation the company could soon be put on the auction block.

Homeopathic remedies harmed hundreds of babies, families say, as FDA investigated for years | STAT

Over a 10-year period, from 2006 to 2016, the FDA collected reports of “adverse events” in more than 370 children who had used Hyland's homeopathic teething tablets or gel, a similar product that is applied directly to a baby's gums.

Safety, quality and clinical practice

There's a lesson about one of the testosterone studies released this week that has nothing to do with testosterone: The study on how testosterone affects anemia was designed with an ethical lapse that nobody noticed until the study was complete.